Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ) Cyclically Adjusted Revenue per Share: €0.62 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:2TZ Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd STU:2TZ
71 GF Score
Price €2.42
GF Value €1.64
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Tianjin Pharmaceutical Da Ren Tang Group Cyclically Adjusted Revenue per Share?

Tianjin Pharmaceutical Da Ren Tang Group STU:2TZ -0.82% 71 Cyclically Adjusted Revenue per Share is €0.62 as of Mar. 2026. GuruFocus rates STU:2TZ with a GF Score™ of 71/100 and a GF Value™ of €1.64 (Significantly Overvalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Tianjin Pharmaceutical Da Ren Tang Group's adjusted revenue per share for the three months ended in Mar. 2026 was €0.247. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €0.62 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Tianjin Pharmaceutical Da Ren Tang Group's average Cyclically Adjusted Revenue Growth Rate was -3.60% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -1.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 0.70% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 4.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Tianjin Pharmaceutical Da Ren Tang Group was 14.10% per year. The lowest was -1.60% per year. And the median was 7.90% per year.

As of today (2026-07-29), Tianjin Pharmaceutical Da Ren Tang Group's current stock price is €2.42. Tianjin Pharmaceutical Da Ren Tang Group's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €0.62. Tianjin Pharmaceutical Da Ren Tang Group's Cyclically Adjusted PS Ratio of today is 3.90.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Tianjin Pharmaceutical Da Ren Tang Group was 5.72. The lowest was 1.42. And the median was 2.65.


Tianjin Pharmaceutical Da Ren Tang Group  (STU:2TZ) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Tianjin Pharmaceutical Da Ren Tang Group's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=2.42/0.62
=3.90

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Tianjin Pharmaceutical Da Ren Tang Group was 5.72. The lowest was 1.42. And the median was 2.65.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Tianjin Pharmaceutical Da Ren Tang Group Cyclically Adjusted Revenue per Share Related Terms


Tianjin Pharmaceutical Da Ren Tang Group Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Tianjin Pharmaceutical Da Ren Tang Group's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tianjin Pharmaceutical Da Ren Tang Group Cyclically Adjusted Revenue per Share Chart

Tianjin Pharmaceutical Da Ren Tang Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.28 0.34 0.52 0.62 0.58

Tianjin Pharmaceutical Da Ren Tang Group Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.63 0.59 0.53 0.58 0.62

STU:2TZ vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Tianjin Pharmaceutical Da Ren Tang Group's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tianjin Pharmaceutical Da Ren Tang Group Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tianjin Pharmaceutical Da Ren Tang Group's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Tianjin Pharmaceutical Da Ren Tang Group's Cyclically Adjusted PS Ratio falls into.


STU:2TZ
71GF Score
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd STU:2TZ
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tianjin Pharmaceutical Da Ren Tang Group Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Tianjin Pharmaceutical Da Ren Tang Group's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.247/116.3033*116.3033
=0.247

Current CPI (Mar. 2026) = 116.3033.

Tianjin Pharmaceutical Da Ren Tang Group Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.286 101.400 0.328
201609 0.264 102.400 0.300
201612 0.250 102.600 0.283
201703 0.255 103.200 0.287
201706 0.261 103.100 0.294
201709 0.224 104.100 0.250
201712 0.230 104.500 0.256
201803 0.275 105.300 0.304
201806 0.253 104.900 0.281
201809 0.255 106.600 0.278
201812 0.277 106.500 0.302
201903 0.301 107.700 0.325
201906 0.296 107.700 0.320
201909 0.278 109.800 0.294
201912 0.296 111.200 0.310
202003 0.276 112.300 0.286
202006 0.267 110.400 0.281
202009 0.271 111.700 0.282
202012 0.269 111.500 0.281
202103 0.310 112.662 0.320
202106 0.300 111.769 0.312
202109 0.294 112.215 0.305
202112 0.281 113.108 0.289
202203 0.352 114.335 0.358
202206 0.346 114.558 0.351
202209 0.326 115.339 0.329
202212 0.467 115.116 0.472
202303 0.379 115.116 0.383
202306 0.325 114.558 0.330
202309 0.280 115.339 0.282
202312 0.408 114.781 0.413
202403 0.344 115.227 0.347
202406 0.311 114.781 0.315
202409 0.272 115.785 0.273
202412 0.290 114.893 0.294
202503 0.243 115.116 0.246
202506 0.185 114.907 0.187
202509 0.160 115.471 0.161
202512 0.196 115.832 0.197
202603 0.247 116.303 0.247

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €0.62 mean?
Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ) has a Cyclically Adjusted Revenue per Share of €0.62 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Tianjin Pharmaceutical Da Ren Tang Group and its competitors.
Is Tianjin Pharmaceutical Da Ren Tang Group's Cyclically Adjusted Revenue per Share too high?
Tianjin Pharmaceutical Da Ren Tang Group's current Cyclically Adjusted Revenue per Share is €0.62. Overall, Tianjin Pharmaceutical Da Ren Tang Group has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tianjin Pharmaceutical Da Ren Tang Group's Cyclically Adjusted Revenue per Share compare to ZTS?
Tianjin Pharmaceutical Da Ren Tang Group's Cyclically Adjusted Revenue per Share of €0.62 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Tianjin Pharmaceutical Da Ren Tang Group and its competitors. Tianjin Pharmaceutical Da Ren Tang Group's current Cyclically Adjusted Revenue per Share is €0.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tianjin Pharmaceutical Da Ren Tang Group stock overvalued right now?
Based on GuruFocus' analysis, Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.64, compared to a current price of €2.42 — trading 47.6% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is €0.62. Tianjin Pharmaceutical Da Ren Tang Group's overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ), the current Cyclically Adjusted Revenue per Share is €0.62 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ) Overvalued in 2026?

Based on GuruFocus' analysis, Tianjin Pharmaceutical Da Ren Tang Group stock appears to be overvalued. The current stock price of €2.42 is trading 47.6% above its estimated GF Value™ of €1.64. GuruFocus considers Tianjin Pharmaceutical Da Ren Tang Group to be Significantly Overvalued.

Key valuation signals for STU:2TZ:

  • Cyclically Adjusted Revenue per Share: €0.62
  • GF Value™: €1.64 vs. price of €2.42 (47.6% above fair value)
  • GF Score™: 71/100 with 5 warning signs

No single metric tells the full story. See the STU:2TZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Tianjin Pharmaceutical Da Ren Tang Group Business Description

Other Exchanges T14:Singapore600329:China
Address No. 17 Baidi Road, Darentang Building, Nankai District, Tianjin, CHN, 300193
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is a pharmaceutical manufacturing company. The company is engaged in the production and sale of traditional Chinese medicine, Western medicine, healthcare products, and investment holding. It operates in two segments, namely the Chinese Medicine segment and the Western Medicine segment. The Chinese Medicine segment manufactures Chinese pharmaceutical products under brands owned by the group. The Western Medicine segment manufactures Western pharmaceutical products through cooperation with foreign companies. The company earns the majority of its revenue from the sale of Chinese medicine.
71GF Score

Get the complete analysis for STU:2TZ

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.42
Price
€1.64
GF Value